Abstract:Aerobic glycolysis is an emerging hallmark of many human cancers, as cancer cells are defined as a "metabolically abnormal system". Carbohydrates are metabolically reprogrammed by its metabolizing and catabolizing enzymes in such abnormal cancer cells. Normal cells acquire their energy from oxidative phosphorylation, while cancer cells acquire their energy from oxidative glycolysis, known as the "Warburg effect". Energy-metabolic differences are easily found in the growth, invasion, immune escape and anti-tumor drug resistance of cancer cells. The glycolysis pathway is carried out in multiple enzymatic steps and yields two pyruvate molecules from one glucose (Glc) molecule by orchestral reaction of enzymes. Uncontrolled glycolysis or abnormally activated glycolysis is easily observed in the metabolism of cancer cells with enhanced levels of glycolytic proteins and enzymatic activities. In the "Warburg effect", tumor cells utilize energy supplied from lactic acid-based fermentative glycolysis operated by glycolysis-specific enzymes of hexokinase (HK), keto-HK-A, Glc-6-phosphate isomerase, 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, phosphofructokinase (PFK), phosphor-Glc isomerase (PGI), fructose-bisphosphate aldolase, phosphoglycerate (PG) kinase (PGK)1, triose phosphate isomerase, PG mutase (PGAM), glyceraldehyde-3-phosphate dehydrogenase, enolase, pyruvate kinase isozyme type M2 (PKM2), pyruvate dehydrogenase (PDH), PDH kinase and lactate dehydrogenase. They are related to glycolytic flux. The key enzymes involved in glycolysis are directly linked to oncogenesis and drug resistance. Among the metabolic enzymes, PKM2, PGK1, HK, keto-HK-A and nucleoside diphosphate kinase also have protein kinase activities. Because glycolysis-generated energy is not enough, the cancer cell-favored glycolysis to produce low ATP level seems to be non-efficient for cancer growth and self-protection. Thus, the Warburg effect is still an attractive phenomenon to understand the metabolic glycolysis favored in cancer. If the basic properties of the Warburg effect, including genetic mutations and signaling shifts are considered, anti-cancer therapeutic targets can be raised. Specific therapeutics targeting metabolic enzymes in aerobic glycolysis and hypoxic microenvironments have been developed to kill tumor cells. The present review deals with the tumor-specific Warburg effect with the revisited viewpoint of recent progress.

Features of Energy Metabolism and Clinical Application in Cancer Growth

The Role of Aberrant Metabolism in Cancer: Insights into the Interplay Between Cell Metabolic Reprogramming, Metabolic Syndrome, and Cancer

Energy Metabolism of Malignant Tumor Cells and Its Significance

Altered metabolism in cancer: insights into energy pathways and therapeutic targets

The hallmarks of cancer metabolism: Still emerging

Cancer Metabolism: Phenotype, Signaling and Therapeutic Targets

Mechanisms of Metabolic Reprogramming in Cancer Cells Supporting Enhanced Growth and Proliferation

Aberrant Energy Metabolism in Tumors and Potential Therapeutic Targets

Dysregulated metabolism contributes to oncogenesis

Cancer metabolism and carcinogenesis

Research Advances on Epigenetics and Cancer Metabolism.

Metabolic catastrophe as a means to cancer cell death

Revisited Metabolic Control and Reprogramming Cancers by Means of the Warburg Effect in Tumor Cells

The Role for Myc in Coordinating Glycolysis, Oxidative Phosphorylation, Glutaminolysis, and Fatty Acid Metabolism in Normal and Neoplastic Tissues

Effects of Glucose Metabolism, Lipid Metabolism, and Glutamine Metabolism on Tumor Microenvironment and Clinical Implications

Reprogramming of glucose, fatty acid and amino acid metabolism for cancer progression

Tumor Energy Metabolism: Implications for Therapeutic Targets

Targeting cellular metabolism to improve cancer therapeutics

Bioenergetic alteration in gastrointestinal cancers: The good, the bad and the ugly

Glycolysis, the sweet appetite of the tumor microenvironment